YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-Comparison Study in Patients With Non-Erosive Gastroesophageal Reflux Disease.

Trial Profile

YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-Comparison Study in Patients With Non-Erosive Gastroesophageal Reflux Disease.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Nov 2011

At a glance

  • Drugs Famotidine (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2007 Status changed from in progress to completed.
    • 28 Sep 2006 Status change
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top